Wilson HTM raises 12 mth target to $4.85.
Now assuming $11,500 patient for CF, but still $7,500 for bronch. So room fora large upgrage to assumptions pending results in that area.
6.6 percent is a massive result. Their main competitor which is already commercial is at 5.8 percent. And Bronchotol actually also improves efficacy of that drug by an additional 5 percent.
I think this stock will continue to run over the next few weeks.
pxs - wilson htm lifts target $4.85
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
